{"id":"W1978580856","doi":"10.1200/jco.2006.10.2871","title":"Phase II Trial of Sorafenib in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Nasopharyngeal Carcinoma","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":260,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; London Health Sciences Centre; University Health Network","funders":"","keywords":"Medicine; Sorafenib; Internal medicine; Nasopharyngeal carcinoma; Oncology; Head and neck squamous-cell carcinoma; Carcinoma; Adverse effect; Chemotherapy; Progressive disease; Head and neck cancer; Response Evaluation Criteria in Solid Tumors; Radiation therapy; Stage (stratigraphy); Gastroenterology; Hepatocellular carcinoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001437327,0.001454447,0.002455295,0.0002341619,0.0002845407,0.0007732662,0.000671138,0.0008391252,0.002853812],"category_scores_gemma":[0.0009723211,0.0003832215,0.000995148,0.0002406076,0.0005806175,0.0004124411,0.0002810345,0.001875621,0.0005861639],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008085138,"about_ca_system_score_gemma":0.001731556,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008452583,"about_ca_topic_score_gemma":0.002230134,"domain_scores_codex":[0.9996624,0.0001637512,0.0000216094,0.00005717782,0.00002950119,0.00006555888],"domain_scores_gemma":[0.9993348,0.00011794,0.0001512793,0.00003469626,0.00005116607,0.0003101718],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7983013,0.03040954,0.01357111,0.001818095,0.002304945,0.0007040762,0.0004070942,0.003429305,0.03596069,0.0002630635,0.006233193,0.1065975],"study_design_scores_gemma":[0.8132908,0.1638562,0.01305405,0.00005305938,0.0005934025,0.0006462788,0.00006565294,0.002410503,0.003369664,0.0001376995,0.002497579,0.00002516042],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9931182,0.0030277,0.0003875091,0.0003538497,0.0001130922,0.001610607,0.0005359103,0.00005336374,0.000799872],"genre_scores_gemma":[0.9916607,0.001698048,0.001066241,0.000477855,0.0001603878,0.001864752,0.001599998,0.00001440451,0.001457667],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002853812,"threshold_uncertainty_score":0.009546936,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.12490601408766,"score_gpt":0.4508927971275671,"score_spread":0.3259867830399071,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}